复方黄柏液联合化学药治疗溃疡性结肠炎的Meta分析 点击下载
论文标题: 复方黄柏液联合化学药治疗溃疡性结肠炎的Meta分析
英文标题:
中文摘要: 目的:系统评价复方黄柏液联合化学药治疗溃疡性结肠炎(UC)的疗效和安全性,为临床提供循证参考。方法:计算机检索中国生物医学文献数据库(CBM)、万方数据库、中文科技期刊全文数据库(VIP)、中国期刊全文数据库(CJFD)、PubMed、EMBase和 Cochrane 图书馆,收集复方黄柏液联合化学药(试验组)对比单纯化学药(对照组)治疗UC的随机对照试验(RCT),筛选文献、提取资料并按照Cochrane reviewer’s handbook 5.1.0评价质量后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入8项RCT,合计737例患者。Meta分析结果显示,试验组患者总有效率显著高于对照组,差异有统计学意义[OR=4.69,95%CI(3.00,7.34),P<0.001];两组患者不良反应发生率比较,差异无统计学意义[OR=0.94,95%CI(0.48,1.84),P=0.86]。结论:复方黄柏液联合化学药治疗UC疗效优于单纯化学药,但两者安全性相当。
英文摘要: OBJECTIVE: To systematically evaluate the clinical efficacy and safety of Compound Huangbo liquid combined with chemical medicine in the treatment of ulcerative colitis (UC), and to provide evidence-based reference. METHODS: Retrieved from CBM, Wanfang Database, VIP, CJFD, PubMed, EMBase and Cochrane Library, randomized controlled trials (RCTs) about Compound Huangbo liquid combined with chemical medicine (trial group) vs. chemical medicine alone (control group) in the treatment of UC were collected. Meta-analysis was performed by using Rev Man 5.3 statistical sofetware after literature scanning, data extraction and quality evaluation according to Cochrane reviewer’s handbook 5.1.0. RESULTS: A total of 8 RCTs were included, involving 737 patients. The results of Meta-analysis showed that, response rate of trial group was significantly higher than that of control group, with statistical significance [OR=4.69,95%CI(3.00,7.34),P<0.001]; there was no statistical significance in the incidence of ADR between 2 groups [OR=0.94,95%CI(0.48,1.84),P=0.86]. CONCLUSIONS: Compound Huangbo liquid combined with chemical medicine is better than chemical medicine alone for UC, and both have similar safety.
期刊: 2017年第28卷第30期
作者: 李辉标,陈新林,陈慕媛,丘振文,李得堂,唐洪梅
英文作者: LI Huibiao,CHEN Xinlin,CHEN Muyuan,QIU Zhenwen,LI Detang,TANG Hongmei
关键字: 复方黄柏液;溃疡性结肠炎;Meta分析;疗效;安全性
KEYWORDS: Compound Huangbo liquid; Ulcertive colitis; Meta-analysis; Therapeutic efficacy; Safety
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!